The study further demonstrated that ES-SCLC patients exhibiting ctDNA clearance or TP53/RB1 co-mutation derived greater benefit from first-line immunotherapy post-radiotherapy (34). This evidence concerns the gene RB1 and small cell lung carcinoma.